Yang et al. developed a novel prognostic model for risk assessment in patients with pulmonary arterial hypertension (PAH), integrating right ventricle-pulmonary artery (RV-PA) coupling and inferior vena cava (IVC) diameter. In a single-center prospective study including 98 patients followed for a median of 26 months, they applied a three-layer echocardiographic model incorporating the tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio and IVC diameter. Their model demonstrated superior prognostic accuracy (C-index = 0.76) compared to the ESC/ERS 2022 three-strata and simplified four-strata models (C-index = 0.66 and 0.61, respectively). Patients with lower TAPSE/PASP and a dilated IVC exhibited a significantly higher risk of clinical worsening (HR = 15.1, p < 0.001). Despite its potential, the study presents limitations: the cohort predominantly consisted of female patients (84.7%) with PAH associated with congenital heart disease (71.4%). Additionally, IVC diameter is already utilized to estimate right atrial pressure, raising concerns about the added prognostic value of the proposed model. Moreover, while echocardiographic parameters offer a non-invasive assessment, they remain operator-dependent and less precise than gold-standard techniques such as right heart catheterization and cardiac magnetic resonance. Yang et al.’s work provides valuable insights into PAH risk stratification, yet a more comprehensive approach integrating invasive hemodynamic assessment and advanced imaging may enhance prognostic accuracy. Future studies should externally validate the model and explore clustering analyses to improve patient phenotyping, ultimately refining risk prediction and clinical decision-making in PAH.